Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 4, 2015, Pages 452-462

  Donvito, Giulia ^a   Bettoni, Isabella ^a   Comelli, Francesca ^a   Colombo, Anita ^a   Costa, Barbara ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Allodynia; Diabetes; Endocannabinoid; Insulin; Insulitis; Mast cell; Nerve growth factor; Neuropathy; Oxidative stress; Palmitoylethanolamide

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1, 3, 3 TRIMETHYLBICYCLO [2.2.1] HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CAPSAZEPINE; INSULIN; NERVE GROWTH FACTOR; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIMONABANT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ANALGESIC AGENT; ETHANOLAMINE DERIVATIVE; PALMITIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULITIS; MALE; MAST CELL DEGRANULATION; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PANCREAS ISLET CELL; SCIATIC NERVE; STREPTOZOTOCIN INDUCED INSULIN DEPENDENT DIABETES MELLITUS; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DRUG EFFECTS; HYPERALGESIA; METABOLISM; PAIN; PAIN MEASUREMENT; PANCREAS ISLET; PATHOPHYSIOLOGY;

ANALGESICS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ETHANOLAMINES; HYPERALGESIA; ISLETS OF LANGERHANS; MALE; MICE; NERVE GROWTH FACTOR; PAIN; PAIN MEASUREMENT; PALMITIC ACIDS; SCIATIC NERVE;

EID: 84929628172     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150429111537     Document Type: Article

References (41)

1. International Diabetes Federation. IDF Diabetes Atlas: 6th edn Brussels, Belgium: International Diabetes Federation, 2013.
2. Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 2009; 6: 638-47.
3. Smith HS, Argoff CE. Pharmacological treatment of diabetic neuropathic pain. Drugs 2011; 71: 557-89.
4. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has antiallodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1: TRPV1 and PPARγ receptors and neurotrophic factors. Pain 2008; 139: 541-50.
5. Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 2002; 137: 413-20.
6. D'Agostino G, La Rana G, Russo R, et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. JPET 2007; 322: 1137-43.
7. Lambert DM, Vandervoorde S, Diependaele G, Govaerts SJ, Robert AR. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 2001; 42: 321-7.
8. Di Marzo V, Melck D, Orlando P, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 2001; 358: 249-55.
9. Genovese T, Esposito E, Mazzon E, et al. Effects of palmitoylethanolamide on signalling pathways implicated in the development of spinal cord injury. JPET 2008; 326: 12-23.
10. D'Agostino G, La Rana G, Russo R, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 2009; 613: 54-9.
11. Lo Verme J, Russo R, La Rana G, et al. Rapid broad -spectrum analgesia through activation of peroxisome proliferator-activated receptor-α. JPET 2006; 319: 1051-61.
12. Jack DB. Aliamides: a new approach to the treatment of inflammation. Drug News Persp 1996; 9: 93-8.
13. Calabro RS, Gervasi G, Marino S, Mondo PN, Bramanti P. Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Med 2010; 11: 781- 4.
14. Indraccolo U, Barbieri F. Effect of palmitoylethanolamidepolydatin combination on chronic pelvic pain associated with endometriosis: Preliminary observations. Eur J Obstet Gynecol Reprod Biol 2010; 150: 76-9.
15. Darmani NA, Izzo AA, Degenhardt B, et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamide, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 2005; 48: 1154-63.
16. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-10.
17. Collin M, Abdelrahman M, Thiemermann C. Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock. Eur J Pharmacol 2004; 486: 233-5.
18. Caprioli A, Coccurello R, Rapino C, et al. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. J Pharmacol Exp Ther 2012; 342: 188-95.
19. Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96: 14228-33.
20. Di Marzo V, Lastres-Becker I, Bisogno T, et al. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 2001; 420: 123-31.
21. Baik SH, Park IB, Choi KM, et al. BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice. Diabetes Res Clin Pract 1999; 46: 91-7.
22. Kim KS, Kang Y, Choi SE, et al. Modulation of glucocorticoidinduced GAD expression in pancreatic beta-cells by transcriptional activation of the GAD67 promoter and its possible effect on the development of diabetes. Diabetes 2002 51: 2764-72.
23. Skaper SD, Facci L, Fusco M, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 2014; 22: 79-94.
24. Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014; 19: 328-35.
25. Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat 2014; 2014: 849623.
26. Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat 2014; 2014: 854560.
27. Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993; 53: 81-8.
28. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the antiinflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-19.
29. Paterniti I, Impellizzeri D, Crupi R, et al. Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J Neuroinflammation 2013; 1: 10-20.
30. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-81.
31. Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2- arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998; 353: 23-31.
32. Lo Verme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci 2005; 77: 1685-98.
33. Khomula EV, Viatchenko-Karpinski VY, Borisyuk AL, Duzhyy DE, Belan PV, Voitenko NV. Specific functioning of Cav3.2 Ttype calcium and TRPV1 channels under different types of STZdiabetic neuropathy. Biochim Biophys Acta 2013; 1832: 636-49.
34. Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferatoractivated receptor gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005; 161: 113-22.
35. Pittenger G, Vinik A. Nerve growth factor and diabetic neuropathy. Exp Diab Res 2003; 4: 271-85.
36. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284: 2215-21.
37. Kobori M, Masumoto S, Akimoto Y, Takahashi Y. Dietary quercetin alleviates diabetic symptoms and reduces streptozotocininduced disturbance of hepatic gene expression in mice. Mol Nutr Food Res 2009; 53: 859-68.
38. Kang HS, Yang H, Ahn C, Kang HY, Hong EJ, Jaung EB. Effects of xenoestrogens on streptozotocin-induced diabetic mice. J Physiol Pharmacol 2014; 65: 273-82.
39. Gupta D, Kurhe Y, Radhakrishnan M. Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system. Physiol Behav 2014; 129: 73-8.
40. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993; 39: C145-7.
41. Geoffrey R, Jia S, Kwitek AE, et al. Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol 2006; 177: 7275-86.